Lilly Acquires 4E Therapeutics to Advance Non-Opioid MNK Inhibitor Pipeline for Chronic Pain
核心洞察
Eli Lilly has acquired Austin-based 4E Therapeutics (搜索), gaining a pipeline of orally available MNK (搜索) inhibitors targeting chronic pain (搜索) through the MNK-eIF4E (搜索) signaling pathway in peripheral sensory neurons.
4E's lead compound, 4ET1103 (搜索), is the first MNK (搜索) inhibitor developed for pain to reach human clinical trials, demonstrating a favorable safety profile in a Phase 1 study.
The acquisition combines 4E's innovative non-opioid approach with Lilly's clinical development, translational, and global commercial capabilities to accelerate new therapies for chronic pain (搜索) patients.
Eli Lilly and Company has acquired 4E Therapeutics (搜索), an Austin-based neuroscience company developing next-generation, non-opioid treatments for chronic pain (搜索), the companies announced Tuesday. The acquisition brings together 4E's innovative pipeline of orally available MNK (搜索) inhibitors with Lilly's broad neuroscience capabilities and global commercial infrastructure.
The deal marks Lilly's second acquisition of a non-opioid pain drugmaker in as many years, following its May 2025 purchase of SiteOne Therapeutics (搜索) in a transaction valued at up to $1 billion. Financial terms of the 4E acquisition were not disclosed.
Targeting the MNK (搜索)-eIF4E (搜索) Pathway in Peripheral Neurons
4E Therapeutics (搜索) has built its pipeline around a novel mechanism of action: inhibiting MNK (搜索) (MAP kinase-interacting kinase) enzymes to modulate the MNK-eIF4E (搜索) signaling pathway specifically in peripheral sensory neurons. This approach is designed to deliver meaningful pain relief while avoiding the central nervous system effects associated with many existing pain therapeutics, including the addiction risks linked to opioid-based treatments.
The company's lead compound, 4ET1103 (搜索), holds the distinction of being the first MNK (搜索) inhibitor developed to treat pain to advance to human clinical trials. In a Phase 1 study, 4ET1103 demonstrated a favorable safety profile. The asset is currently in development for nerve damage-related pain.
Beyond 4ET1103 (搜索), 4E's portfolio includes experimental treatments targeting migraines and acute pain, broadening the potential applications of its MNK (搜索) inhibition platform.
From Academic Research to Clinical Development
4E Therapeutics (搜索) was founded with the goal of developing innovative, non-opioid therapies that address the underlying neurological mechanisms driving chronic pain (搜索). The company raised just under $10 million through private funding and grants from the National Institutes of Health to advance its research.
"We founded 4E Therapeutics (搜索) with a simple but ambitious goal: to develop innovative, non-opioid therapies that address the underlying neurological mechanisms that cause pain," said Joe Price, Co-Founder, President and Chairman of 4E Therapeutics. "Lilly's clinical development, translational, and global commercial capacity — and its deep commitment to tackling the challenges of chronic pain (搜索) for patients — make it the right home for realizing the full potential of this work for patients."
Theodore Price, Ph.D., Co-Founder of 4E Therapeutics (搜索) and Director of the Center for Advanced Pain Studies at The University of Texas at Dallas, highlighted the scientific journey underpinning the acquisition: "Seeing this science — years of research into the molecular events that cause pain to become chronic — advance from basic research to clinical development and now to Lilly's pipeline, provides excitement for the opportunity to accelerate new therapies to patients living with chronic pain (搜索)."
Lilly's Expanding Neuroscience Footprint
The 4E acquisition reinforces Lilly's deepening commitment to the neuroscience and pain management space. The company's growing portfolio in this area now spans multiple non-opioid mechanisms, including sodium ion channel modulation through the SiteOne Therapeutics (搜索) deal.
However, the path forward in pain drug development remains challenging. Lilly has discontinued two pain drug candidates from its pipeline within the same timeframe as these acquisitions, underscoring the inherent difficulties of advancing novel analgesics through clinical development.
4E's exclusive financial advisor for the transaction was Aquilo Partners LP, with Wilson Sonsini Goodrich & Rosati LLP providing legal counsel.